163 results about "Tumor specific" patented technology

The invention relates to an immune sensitization IRE treatment platform based on NK cell membrane coated manganese carbonate. A manganese carbonate composite nano material is formed by coating the surfaces of manganese carbonate nano particles with cell membranes. According to the invention, higher tumor specificity enrichment is realized, non-target tissue accumulation and systemic toxicity risks are reduced, collaborative integration of tumor targeted delivery, immune activation and IRE ablation is realized, and compared with single IRE, anti-tumor immune response is significantly enhanced.

The application relates to the field of biological preparations, and particularly discloses an immunochromatographic reagent for detecting malignant tumors in urine and application thereof, which is used for solving the problems of poor recognition of tumor specific epitopes, heavy background interference, spectrum overlap and high subjectivity of artificial judgment in the single staining and color development of acridine orange in the detection of urinary exfoliative cells of bladder cancer. The color development reagent comprises A reagent, B reagent, C reagent and D reagent. The A reagent is provided with an antibody complex for target antigens of bladder tumor cells in urine exfoliation and acridine orange. The B reagent comprises a fluorescently labeled secondary antibody composition corresponding to the A reagent and an enzyme-labeled secondary antibody-tyramide deposition amplification composition. In the application, AI imaging analysis is adopted to calibrate layered recognition labels and acridine orange staining negative and positive labels. Through multi-target immunochromatography, two sets of color separation amplification schemes and AI imaging analysis, the application improves the recognition ability of bladder tumor specific epitopes, the image quality and the image analysis accuracy in the detection of urinary exfoliative cells.

Provided herein are immortalized mesenchymal stem cells comprising a replicating recombinant retrovirus. Methods for treating a cell proliferative disorder using these immortalized mesenchymal stem cells are also provided.

The present invention provides compounds of Formula (I) which can be used as CCR8 inhibitors, which can be used as treatment or prevention of cancer using CCR8 inhibitors targeted tumor specific T regulatory cells.

This disclosure relates to a technique for identifying tumor-specific mutations through integrated analysis of next-generation sequencing data using machine learning models. In certain embodiments, a computer implementation method is provided, comprising: generating sequence reads from one or more samples collected from the same patient; generating variant calling files by analyzing the sequence reads corresponding to each of the one or more samples; generating a list of candidate somatic variants by comparing the variant calling files; generating a score for each of the candidate somatic variants in the list of candidate somatic variants using a classification machine learning model, wherein the score is generated based on a plurality of classifications generated by the classification machine learning model; determining the ctDNA status for the patient based on the score, wherein the ctDNA status is either positive or negative; and generating a report providing the ctDNA status for the patient.

The invention provides a multiple detection technology MMDEC for high-sensitivity detection of tumor methylated DNA from samples such as blood, belongs to the field of disease diagnosis markers, and more specifically relates to a method for detecting methylation of target DNA through the following steps: constructing oligonucleotide; the kit comprises a target specific multiple Rooptag primer capable of being complementarily combined with a plurality of tumor specific high-methylated CG island target DNAs (Deoxyribose Nucleic Acid) and a universal tag primer combined with the specific multiple Rooptag primer, wherein the target specific multiple Rooptag primer can be complementarily combined with a plurality of tumor specific high-methylated CG island target DNAs (Deoxyribose Nucleic Acid); the method comprises the following steps: performing exponential amplification on multiple methylation target DNA by using a specific multiple Rooptag primer as a primary primer to obtain a multiple amplification product; performing homogeneity amplification on the obtained multiplex amplification primer by using oligonucleotide (which can be complementarily combined with the linearly amplified target DNA) using a universal tag primer as a secondary primer; and detecting whether an amplification product exists or not through a probe. According to the method disclosed by the invention, MMDEC can be used for early screening and diagnosis of plasma / urine sample tumors, accords with clinical practice on the basis of research results, and has a good clinical application prospect.

The invention relates to the technical field of magnetic particle imaging, in particular to a core-shell nanoprobe and a preparation method and application thereof.The core-shell nanoprobe comprises a magnetic core and a nanoshell which is located outside the magnetic core and has a magnetic shielding response function, and the structure of the nanoshell collapses under the tumor microenvironment condition; the saturation magnetization of the magnetic core is greater than or equal to 50 emu / g, and the coercive force is less than or equal to 5 Oe; the saturation magnetization of the nano shell is less than 50 emu / g, and the coercive force is more than 5 Oe. According to the core-shell nanoprobe, through a unique magnetic core-shell structure design and tumor microenvironment response characteristics, a magnetic shielding layer is formed by using a low-signal nano shell with a response magnetic shielding function, and background signal interference is inhibited. In a tumor microenvironment, the shell structure of the core-shell nanoprobe collapses, the magnetic core is exposed, and a high magnetic signal is released and generated, so that the imaging signal-to-noise ratio is remarkably improved. According to the invention, the bottleneck that the traditional MPI probe is lighted in the whole course can be broken through, the tumor specificity is lighted and positioned, and the problems that the external background of the tumor is high, the contrast ratio is poor, and tiny focuses are difficult to detect are solved.

Therapeutic polypeptides, compositions thereof and methods of use thereof for activating NK cells and treating tumors are provided. The therapeutic polypeptides can include a first domain for binding NKG2D and a second domain for binding a tumor target.

The application discloses a micro serum tumor whole-process screening detection method based on nucleic acid aptamer group comparison, and comprises the following steps: firstly, 24+1 tumor and non-tumor specific nucleic acid aptamer groups are screened by using bidirectional thermal cycle subtraction SELEX technology; data of the specific nucleic acid aptamer groups are used to create a standard database; the specific nucleic acid aptamer groups are mixed in equal proportions to develop 24+1 tumor and non-tumor specific nucleic acid aptamer detection reagents; in the detection process, the detected sample forms a magnetic bead-sample serum protein complex, and then is combined with the aptamer detection reagent; a magnetic bead-serum protein-sample specific nucleic acid aptamer complex is formed, and sample specific nucleic acid aptamer is separated and obtained; and the sample specific nucleic acid aptamer is compared and analyzed with the standard database, so that the sample detection technology method is realized. The method has the advantages of small sample amount, automatic process completion, high throughput, wide tumor screening range and the like, and meets the requirements of high-throughput tumor screening.

The application provides a non-contact pain monitoring mattress and system based on multi-modal physiological signal fusion, the mattress body comprises, from bottom to top, a bottom support layer, a signal shielding layer, a sensing core layer and a breathable skin-friendly layer, the system comprises the non-contact pain monitoring mattress, a low-noise charge amplifier, a fiber demodulator, an edge computing gateway and a cloud analysis center, the data after signal conditioning is transmitted to the edge computing gateway and uploaded to the cloud analysis center, and the cloud analysis center performs quantitative scoring through a tumor-specific pain model.The application has the advantages that no electrode or wearable device needs to be pasted, the skin irritation and psychological burden of traditional monitoring are completely eliminated, the patient compliance is improved, the limitation of subjective evaluation is broken through, an objective pain evaluation method is provided for patients in the late stage / aphasia, multi-modal signal fusion monitoring is used to effectively distinguish pain from ordinary emotional fluctuations, the degree of pain is fed back in real time, the doctor is assisted in dynamically adjusting the dose of analgesic drugs, and the risk of drug overdose and deficiency is reduced.

The invention discloses a tumor specific signal analysis device and equipment for uncertain pulmonary nodules and a storage medium, and relates to the technical field of electrical digital data processing.The device constructs a LungTCR database containing lung cancer tissue enrichment type and blood enrichment type CDR3 sequences through TCR beta chain sequencing and IMGT database comparison, and the LungTCR database is used for analyzing the lung cancer tissue enrichment type and blood enrichment type CDR3 sequences. A basis is provided for tumor specific signal recognition; a Needleman-Wunsch algorithm and an editing distance threshold value are adopted for screening, so that high-precision sequence matching is realized; through quantification of lung cancer tissue scores, blood scores and mutation specificity scores, a TCR feature group with biological significance is formed; and finally, the TCRnodseek plus model trained by clinical and image features is combined, a reliable malignant probability prediction value can be output, the model AUC can reach 0.90 or above, and the model is obviously superior to traditional imaging diagnosis and tumor markers.

Methods are provided for detecting gene deletions and driver mutations using tumor-specific methylation patterns from cell-free DNA and tissue biopsies. The methods exploit the mutual exclusivity between tumor-specific methylation and homozygous gene deletion, enabling detection through absence of expected methylation signals. Applications include detection of MTAP, PTEN, and RB1 deletions, as well as prediction of EGFR single nucleotide (SNV) and small (up to 50 base pair) insertions and deletions (indel) driver mutations, enabling identification of patients eligible for targeted therapies.

The application discloses an ion channel based on a poly-polypeptide skeleton and application thereof, and rational use of the poly-polypeptide main chain length difference of different polymerization degrees and the structure-activity relationship difference of different secondary structures of the poly-polypeptide is used in the poly-polypeptide ion channel of the application, the polymerization degree and the secondary structure of the poly-polypeptide are regulated, the length of the poly-polypeptide and the arrangement of the side chain functional groups are regulated, and then the opening or closing of the poly-polypeptide ion channel is regulated, a responsive poly-polypeptide ion channel is designed by introducing a suitable responsive group into the side chain of the poly-polypeptide, and therefore the tumor-specific activation of the poly-polypeptide ion channel is realized, and inspiration is provided for the design and application of the artificial ion channel.

The application relates to the technical field of medicines, and discloses an application of homoharringtonine in the preparation of a medicine for treating small cell lung cancer, and further provides a medicine for treating small cell lung cancer and containing homoharringtonine. The application discloses an action mechanism of homoharringtonine, an active ingredient of traditional Chinese medicine, against SCLC, and discloses that the traditional Chinese medicine ingredient HHT inhibits a malignant phenotype by targeting tumor-specific glycosylation enzyme MGAT5, provides an innovative perspective of glyco-biology for the research of traditional Chinese medicine against tumors, provides an important scientific basis for the subsequent development and application of homoharringtonine, and provides a new medicine treatment approach for treating small cell lung cancer.

This invention relates to the field of organic small molecule fluorescent probe technology, specifically to a neuron-specific dual-targeting fluorescent probe targeting the AChR of cholinergic neurons and its applications. The fluorescent probe, whose structure follows general formula I, is characterized by its dual-targeting structure, making it particularly suitable for the identification and labeling of cholinergic neurons. Furthermore, this fluorescent probe exhibits significant advantages in multiple application scenarios, such as cell imaging, protein and organelle labeling, tumor-specific recognition, and photodynamic therapy, with its potential application value in neuroimaging being particularly prominent. This fluorescent probe is expected to advance the development of neurobiology, disease diagnosis, and treatment methods, and has promising application prospects.

Tumor-selective expression of therapeutic molecules by bacteria is achieved by one or more AND, NOR, OR, NOT and / or NAND gate genetic circuits. The therapeutic molecules can be proteins, metabolites or catabolites, and may also be immunotherapeutics or immunotherapeutic cytotoxins. Single or multiple expression components may be used. Tumor selective expression of multimeric proteins utilizes multimerization as to complete the genetic circuit. Genetic circuits that are unlinked, function to achieve a combined effect on specificity of delivery of antitumor therapeutic molecules. Compositions and methods to generate silica, PEG and Poly-HPMA coated bacteria are also provided. Compositions and methods for selectively sensing or imaging tumors are also described.

This invention discloses a T-cell training method based on tumor organ-on-a-chip. The method includes: preparing an organ-on-a-chip with a micropillar array and a biomimetic fishbone structure; introducing primary tumor cells from a patient into the chip, causing them to spontaneously form uniform three-dimensional tumor spheroids; dynamically pumping pre-activated peripheral blood lymphocytes from the same patient into the chip and co-culturing them with the tumor spheroids; collecting the co-cultured lymphocytes and repeating the co-culture process multiple times to obtain a lymphocyte population with enhanced anti-tumor activity. This invention utilizes organ-on-a-chip technology to highly simulate the dynamic tumor immune microenvironment in vivo. Through multiple cycles of "training," it effectively activates and expands tumor-specific T cells, avoiding immune exhaustion, and providing a highly efficient and controllable new platform for personalized immunotherapy of solid tumors.

Disclosed herein are engineered natural killer cells that have been modified to express chimeric antigen receptors (CARs). The cells optionally contain other modifications that improve tumor specific cytotoxicity and homing to tumor sites. Also contemplated are methods for using the engineered natural killer cells to treat patients with cancer.

The invention discloses a method and a pharmaceutical composition for inhibiting tumor growth by combining an mRNA vaccine and a transforming growth factor-beta (TGF-beta) antibody. The medicine composition comprises an mRNA vaccine for coding a tumor specific antigen and a monoclonal antibody for specifically targeting TGF-beta, and tumor specific immune response induced by the mRNA vaccine is combined with the effect of the TGF-beta antibody for relieving tumor microenvironment immunosuppression, so that the killing ability of a body to tumor cells is remarkably enhanced; the compound provided by the invention can effectively inhibit tumor growth and prolong the lifetime of tumor-bearing individuals, has good safety and tolerance, and provides a new effective strategy for tumor treatment.

The present disclosure provides double stranded nucleic acid compositions incorporating uracil, gemcitabine, and methotrexate (MTX). More specifically, the present disclosure reveals that modification of a double-stranded microRNA nucleotide sequence with 5-fluorouracil, gemcitabine, and methotrexate (MTX) enhances the therapeutic efficacy and tumor specificity of tumor suppression. Thus, the present disclosure provides various nucleic acid (e.g., microRNA) compositions having 5-fluorouracil, gemcitabine, and methotrexate (MTX) incorporated into their nucleic acid sequences, as well as methods of using the same. The disclosure further provides pharmaceutical compositions (e.g., formulations) comprising the modified nucleic acid compositions, and methods for treating cancer, e.g., pancreatic cancer. The method is a platform technology which can be applied to other tumor suppressor genes miRNA and siRNA.

Tumor-specific T cell receptor (TCR) gene transfer enables specific and potent immune targeting of tumor antigens. The canonical cancer-testis antigen, NY-ESO-1, is not expressed in normal tissues but is aberrantly expressed across a broad array of cancer types. It has also been targeted with A2-restricted TCR gene therapy without adverse events or notable side effects. To enable the targeting of NY-ESO-1 in a broader array of HLA haplotypes, we isolated TCRs specific for NY-ESO-1 epitopes presented by four MHC molecules: HLA-A2, -B07, -B18, and -C03. Using these TCRs, we have developed an approach to extend TCR gene therapies targeting NY-ESO-1 to patient populations beyond those expressing HLA-A2.

The invention provides a paclitaxel precursor nano-drug as well as a preparation method and application thereof, and belongs to the technical field of medicinal chemistry. Comprising a paclitaxel dimer prodrug and 7-ethyl10-hydroxy-camptothecin loaded on the paclitaxel dimer prodrug. According to the invention, a paclitaxel dimer prodrug is used as a self-assembly monomer to construct a PTX-SN38 synergistic treatment nano system, and the system has the advantages of dispersibility in water, biocompatibility, tumor specific response, synergistic treatment and the like, and can effectively solve the limitation of paclitaxel and SN38 in anti-tumor treatment.

The invention discloses a nucleic acid molecule which comprises an open reading frame for coding an EBV antigen, and the EBV antigen is a specific antigen which is contained in a diseased cell of an EBV related disease, is coded by an EBV virus genome and is in a cell and on a cell membrane; the EBV antigen comprises LMP1, LMP2A, LMP2B, EBNA-LP, EBNA1, EBNA2, EBNA3A, EBNA3B, EBNA3C, EBNA4, EBNA5, EBNA6, EBNA7 and EBNA8, as well as lipid nanoparticles containing nucleic acid molecules, a pharmaceutical composition and application thereof, and belongs to the technical field of biology. The nucleic acid molecule, the mRNA, the composition containing the nucleic acid molecule, and the lipid nanoparticles can significantly increase the number of tumor specific immune cells, effectively activate immune response, and significantly inhibit tumor growth, and have significant anti-tumor activity for nasopharynx cancer and lymphoma.

The present disclosure provides shared neoantigenic peptides derived from the expression of tumor-specific transposable element, as well as nucleic acids, vaccines, antibodies and immune cells that can be used in cancer therapy.

The present invention relates to the use of parasites and extracellular vesicles obtained from parasites for cancer treatment. The aim of the present invention is to use parasites and extracellular vesicles obtained from parasites in cancer treatment and to load active substances onto the exosomes by using the drug loading capacity of the exosomes and thus to carry the specific drug directly to the target cancer cells without causing any side effects on healthy cells and thereby to increase the bioavailability of the drug to achieve the desired effect in the tumor-specific target area. Within the scope of the present invention, in particular, the infantile leishmania parasite is used as a source of extracellular vesicles.

Disclosed herein are engineered polyfunctional CD4+ T cells / CAR T cells and methods of their use for the treatment of cancers. One embodiment provides a method of producing polyfunctional CD4+ T cells by constitutively activating STAT5A in the cells to induce a polyfunctional phenotype. Also provided is a method of reversing exhaustion in tumor-specific CD4+ T cells by engineering the cells to express Fos, Jun, Nr4a1, or combinations thereof but not express Tox, Pdcd1, Ctla4, Haver2, Lag3, Tigit, Slam6, Nrf4a2, and administering the engineered cells to a subject.

A method of treating a subject having been diagnosed as having cancer with an immunotherapy is described. The method comprises targeting one or more clonal neoantigens selected using a method comprising determining whether a tumour-specific mutation is likely to be clonal in a subject. The method comprises providing sequence data from one or more samples from the subject comprising tumour genetic material, the sequence data comprising for each of the one or more samples, and determining the likelihood that the tumour-specific mutation is clonal as a posterior probability depending on: a prior probability of the mutation being clonal, and the probabilities of observing the sequence data if the tumour-specific mutation is (i) clonal and (ii) non-clonal, in view of a tumour fraction for each of the one or more samples and one or more candidate joint genotypes.

Provided are a method and a combination for one-tube simultaneous detection of tumor-specific gene mutation and methylation, and the use thereof. The method comprises searching a database to select mutation and methylation sites of a cancer driver gene and a cancer suppressor gene, synthesizing capture probes correspondingly paired with a target interval, performing hybrid capture on an amplification product of a sample treated with a restriction endonuclease by using a probe set comprising tumor-specific gene mutation and methylation capture probes, constructing a high-throughput sequencing library containing a target region, and performing high-throughput sequencing to obtain the sequence of a target fragment, so as to obtain the results of methylation, point mutations and indel variation of a cancer-associated gene. The provided method enables one-tube simultaneous detection of mutation and methylation states of a cancer-associated gene in one assay, requires a low content of a gene to be detected, can be used for methylation and mutation detection of a tumor-specific DNA, and has low detection costs and high efficiency.

The invention discloses a CD3 antibody-polypeptide, which is characterized in that an amino acid sequence of a light chain variable region of a CD3 antibody is linked with an amino acid sequence of polypeptide through a triple link of a GGGGS flexible joint; and the CD3 antibody-polypeptide can be coupled with the RNP compound through a chemical bond to form the CD3 antibody-polypeptide-RNP compound. The CD3 antibody-polypeptide-RNP compound is used as a delivery system for gene editing in the TILs cells, in the gene editing process, CD3 antibody-polypeptide has good cell penetrability and stability, an exogenous gene can be efficiently and accurately delivered into a double-chain incision manufactured on a TRAC gene of the TILs cells, cell damage caused by electrotransfection is avoided, and the CD3 antibody-polypeptide-RNP compound can be applied to gene editing of the TILs cells. The prepared TI Ls cells have a higher proportion of memory T cells (CD45RO < + > CD62L < + >) and a higher proportion of tumor specific T cells (CD8 < + >), so that the TI Ls cells have a better tumor killing effect.

The application belongs to the technical field of biomedicine, and relates to a mitochondrion-targeted nano device and a preparation method and application thereof, the nano device comprising a cascade-activated photodynamic molecular beacon and a mitochondrion-targeted delivery carrier, the cascade-activated photodynamic molecular beacon comprising an APE1 cleavage site and a microRNA recognition region. The cascade-activated photodynamic molecular beacon and the mitochondrion-targeted delivery carrier are self-assembled into a complex through electrostatic adsorption, and cascade activation and signal amplification are realized through the dual response of miR-146a / APE1 which is highly expressed in mitochondria of tumor cells. The application triggers precise and controllable cell pyroptosis through tumor-specific signals, reverses the immune-inhibitory microenvironment, converts the 'cold tumor' into a 'hot tumor', significantly improves the effect of cancer immunotherapy, has good biocompatibility and tumor selectivity, and provides a new strategy and tool for precise treatment of cancer.